SEC Form 4 · accession 0001104659-16-159834
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jorge Plutzky M.D.
Director
Period of report
Nov 29, 2016
Accepted (ET)
Nov 30, 2016 · 7:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $25.99 | Nov 29, 2016 | D | 31,182 | D | — | Apr 8, 2025 | Common Stock | 31,182 | 0 | D |
Explanation of responses
- F1One-third of the shares of common stock underlying this stock option award vested on April 8, 2016. The remaining two-thirds of the shares of common stock underlying this option were to vest in equal installments on April 8, 2017 and April 8, 2018.
- F2Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Remarks
See Exhibit 24.1 - Power of Attorney.